The Genitourinary Cancer Channel

Explore the latest updates, including expert interviews and features

The GU Cancer Channel on VJOncology is supported by Exelixis. The GU Cancer Channel is also supported by an educational grant from Pfizer Inc. and Merck KGaA. These supporters have no influence over the production of the content.

Latest videos VJSessions Subtypes Topics Conferences Features Editorial Board

Welcome to the Genitourinary (GU) Cancer Channel!

Explore the latest updates presented at major international congresses in the form of video interviews, podcasts and roundtable discussions featuring members of our expert Editorial Board.

Exciting advances are being made in the field of genitourinary cancer, including checkpoint inhibitor treatments, new non-steroidal anti-androgens, chemoimmunotherapy combinations and predictive biomarkers.

GU Cancer Videos by Subtype

Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Penile Cancer
1:47
Repurposing abiraterone for the treatment of AR+ salivary gland carcinomas
Alfredo Berruti • 21 Mar 2023
1:52
Enhancing the efficacy of immunotherapy in prostate cancer
Scott Tagawa • 16 Apr 2023
2:25
Phase I trial of ARX517, an anti-PSMA ADC, in mCRPC
Scott Tagawa • 16 Apr 2023
2:05
What role will ADCs play in the prostate cancer treatment landscape?
Scott Tagawa • 16 Apr 2023
View All Videos
1:40
Safety of prostate-sparing + reproductive organ-sparing radical cystectomy for MIBC
Carmen Mir Maresma • 15 Mar 2023
1:23
CDH1-mutated clinically advanced urothelial bladder cancer: real-world clinical outcome study
Philippe Spiess • 10 Mar 2023
0:35
Primary analysis of TROPHY-U-01 Cohort 2
Daniel P. Petrylak • 16 Feb 2023
1:08
Robotic radical cystectomy vs open surgery for bladder cancer
Chi-Hang Yee • 8 Mar 2023
View All Videos
2:26
Best of EAU23 abstracts: renal cancer
Carmen Mir Maresma • 15 Mar 2023
2:17
ZIRCO: 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma
Carmen Mir Maresma • 15 Mar 2023
1:27
Unmet needs regarding immunotherapy for renal cell carcinoma
Nazli Dizman • 24 Feb 2023
5:07
Association between time-of-day of ICI infusion and disease outcomes in metastatic RCC)
Nazli Dizman • 24 Feb 2023
View All Videos
2:19
The urological history of chemotherapy for testis tumors in Europe
Juan Gómez Rivas • 16 Mar 2023
1:44
Genomic features of mediastinal germ cell tumors
Lucia Nappi • 16 Feb 2023
1:40
How far away are we from implementing liquid biopsy approaches in GU cancers?
Lucia Nappi • 16 Feb 2023
2:36
Advancements in surgery for GU cancers
Siamak Daneshmand • 16 Feb 2023
View All Videos
0:57
The evolving landscape of viral, immune and molecular biomarkers in penile cancer
Philippe Spiess • 10 Mar 2023
1:16
Predictors of response to surgery for penile cancer
Philippe Spiess • 10 Mar 2023
2:38
Palliative care following penile cancer surgery
Philippe Spiess • 10 Mar 2023
1:45
Results from dataset analysis of CDH1-mutated urothelial carcinoma patients
Andrea Necchi • 18 Feb 2023
View All Videos

Topics

Trial Updates
Molecular Profiling
Immuno-Oncology
Diagnosis
Imaging
2:25
Phase I trial of ARX517, an anti-PSMA ADC, in mCRPC
Scott Tagawa • 16 Apr 2023
1:06
Unanswered questions and unmet needs in prostate cancer
John Michael Bryant • 17 Apr 2023
3:06
Phase II trial of nivolumab with SOC in the management of GG5 prostate cancer
John Michael Bryant • 17 Apr 2023
2:17
ZIRCO: 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma
Carmen Mir Maresma • 15 Mar 2023
View All Videos
1:23
CDH1-mutated clinically advanced urothelial bladder cancer: real-world clinical outcome study
Philippe Spiess • 10 Mar 2023
3:47
PARP inhibitors for metastatic hormone sensitive prostate cancer
Bertrand Tombal • 17 Mar 2023
1:38
From conventional to molecular diagnostics for prostate cancer
Eva Compérat • 7 Mar 2023
2:26
Managing biochemical relapse after radical prostatectomy
Juan Gómez Rivas • 16 Mar 2023
View All Videos
1:52
Enhancing the efficacy of immunotherapy in prostate cancer
Scott Tagawa • 16 Apr 2023
2:25
Phase I trial of ARX517, an anti-PSMA ADC, in mCRPC
Scott Tagawa • 16 Apr 2023
2:05
What role will ADCs play in the prostate cancer treatment landscape?
Scott Tagawa • 16 Apr 2023
1:06
Unanswered questions and unmet needs in prostate cancer
John Michael Bryant • 17 Apr 2023
View All Videos
3:00
Towards the delivery of comprehensive cancer centers – what it means for prostate cancer
Tit Albreht • 29 Mar 2023
5:35
EU Cancer Plan and what it means for prostate cancer
Tit Albreht • 29 Mar 2023
2:11
Identifying optimal candidates for active surveillance in prostate cancer
Anthony Victor D'Amico • 16 Feb 2023
1:09
Liquid biopsy for prostate cancer
David M. Nanus • 16 Feb 2023
View All Videos
2:17
ZIRCO: 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma
Carmen Mir Maresma • 15 Mar 2023
1:52
Active surveillance for Gleason grade 2 prostate cancer
Juan Gómez Rivas • 16 Mar 2023
5:41
Diagnosing and treating castration resistant prostate cancer
Juan Gómez Rivas • 16 Mar 2023
3:50
The role of PSMA PET in recurrent prostate cancer
Ravi Madan • 3 Mar 2023
View All Videos

Conferences

ESMO 2022
EAU 2022
ASCO 2022
AACR 2022
GU Cancers 2022
ESMO 2021
0:22
The unmet needs of patients with prostate cancer
Daniel Petrylak • 10 Sep 2022
1:37
ARCHES: OS in mHSPC who recieved prior ADT and reached low PSA further treated with enzalutamide
Daniel Petrylak • 11 Sep 2022
1:05
Cohort 1 LITESPARK-003: belzutifan + cabozantinib 1L treatment for advanced RCC
Toni Choueiri • 12 Sep 2022
1:17
DS-7300 demonstrates durable antitumor activity in advanced solid tumors
Toshihiko Doi • 10 Sep 2022
View All Videos
2:15
Analyzing the role of oncolytic viruses in prostate cancer
Geertje Van Der Horst • 28 Jun 2022
2:40
Limitations of oncolytic viral therapy
Geertje Van Der Horst • 28 Jun 2022
4:22
Ongoing studies assessing oncolytic virotherapy in urological malignancies
Geertje Van Der Horst • 28 Jun 2022
2:30
The importance of TURBT in bladder cancer management
Kevin Gallagher • 29 Jun 2022
View All Videos
1:13
Promising future of PSMA for prostate cancer
Eugene Shenderov • 10 Jun 2022
6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
1:59
Next steps for belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
13:17
Belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
View All Videos
0:18
Future research directions for the novel PD-1 and CTLA-4 bispecific checkpoint inhibitor, MEDI5752
Ben Tran • 21 Apr 2022
4:28
Update on PETRA trial investigating a next-generation PARP1 select inhibitor
Timothy Yap • 13 Apr 2022
3:30
Radionuclide conjugates 225Ac-J591 and 177Lu-PSMA-I&T for mCRPC
Scott Tagawa • 11 Apr 2022
1:14
Anti-CAIX immune restoring CAR T-cells reverse immunosuppressive TME
Yufei Wang • 11 Apr 2022
View All Videos
3:42
ctDNA level variation as an early predictor of survival in patients with mCRPC
Vincenza Conteduca • 15 Feb 2022
0:53
Unanswered questions in the management of clear cell RCC
Mehmet Bilen • 19 Feb 2022
1:18
URO-12: Importance of collaboration between institutions in clinical trials
Massimo Di Maio • 3 Mar 2022
2:20
Future of PARP inhibitors for urothelial carcinoma
Massimo Di Maio • 3 Mar 2022
View All Videos
5:28
Importance of real-world data in clinical trials
Janet E. Brown • 19 Sep 2021
2:21
PRISM: importance of investigating the scheduling of treatment regimens for RCC
Janet E. Brown • 19 Sep 2021
2:34
First-line treatments for patients with mHSPC and mCRPC
Richard Cathomas • 27 Sep 2021
2:06
SAKK 08/16: darolutamide maintenance therapy for previously treated patients with mCRPC
Richard Cathomas • 27 Sep 2021
View All Videos

The GU Cancer Channel on VJOncology is supported by Exelixis. The GU Cancer Channel is also supported by an educational grant from Pfizer Inc. and Merck KGaA.

These supporters have no influence over the production of the content.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals